Jena, June 15, 2010 – Analytik Jena AG and SIRS-Lab GmbH, also based in Jena, will be strengthened by working together in the field of molecular sepsis diagnostics. As part of this cooperation, Analytik Jena subsidiary AJ Innuscreen GmbH will provide the partner with a platform for automated isolation of nucleic acids with the associated reagent system worth almost half a million euro.

“In the field of sepsis diagnostics, speed plays a vital role in identifying infections and detecting pathogens. Analytik Jena's cooperation with SIRS-Lab offers great potential for the challenging area of diagnostics”, commented Klaus Berka, CEO of Analytik Jena AG.

SIRS-Lab is a Jena-based biotechnology company which develops and produces test systems for molecular diagnosis of life-threatening infections. SIRS-Lab is a member of the German Sepsis Society and works with many internationally recognized partners. One significant partner is the university hospital of the Friedrich Schiller University of Jena, which in January 2010 received the green light from an international jury of experts to develop an integrated research and treatment center for sepsis and related illnesses. This development is focused primarily on enabling rapid and targeted antibiotic therapy for sepsis.

“Analytik Jena provides us with special reagents and instruments, tailored to our developments, for the fully automated extraction of DNA in whole blood samples. The clinical studies currently underway to validate the test should create the conditions to start marketing our sepsis diagnostics very soon”, explained Barbara Staehelin, CEO of SIRS-Lab GmbH.

Analytik Jena AG concentrates its biotechnological expertise in the Life Science division. Its service includes automated individual and complete solutions for molecular diagnostics. The wide range of products is made possible by synergies between Analytik Jena and its subsidiaries AJ Cybertron, AJ Innuscreen, AJ Roboscreen, AJ eBiochip, CyBio AG and Biometra GmbH. AJ Innuscreen, headquartered in Berlin, was founded in 2005 for the development and manufacture of kits for molecular diagnostics.

• TOptical and qTower expand the life science portfolio with real-time PCR technology
• Analytical Instrumentation business unit premiers the SPECORD^® 200 PLUS
• ENMOhydro: an optimized software solution for water quality measurement networks

Jena/Munich, March 23, 2010 — Analytik Jena AG is continuing its product offensive at this year's "analytica" trade fair. The company will be premiering two new systems for carrying out real-time PCR, thus enhancing the life science portfolio with products that boast high revenue potential. The two systems, which are used in the real-time quantification of nucleic acids, are based on the standard PCR technology used by the Biometra subsidiary, as well as on Analytik Jena's rapid PCR technology. The patented rapid PCR technology from Analytik Jena increases analysis times by 300 to 500 percent compared to conventional processes. The products are licensed for research applications and will be available in early summer 2010.

"The acquisition of the real-time PCR license production and sales of these products is a key milestone for the strategic direction of our life science business and serves as a foundation for further significant revenue growth," said Klaus Berka, CEO of Analytik Jena AG.

Real-time PCR, which relies on a fluorescent signal quantification technique, has been used for amplifying and detecting DNA and RNA in molecular biology applications since the early 90s. This process technology is an established standard in the field of molecular diagnostics.

"Bioanalytical systems and molecular diagnostic reagents represent a huge growth market. The demand for high-end products to serve this segment will increase enormously over the next few years," added Berka. "We're pleased to be able to offer our life science customers this technology as of today."

Together with the subsidiaries AJ Blomesystem GmbH and Biometra GmbH, Analytik Jena is well positioned at this year's analytica and will be presenting a range of additional company-wide product innovations. SPECORD^® PLUS represents a new generation of the tried and tested UV-VIS dual beam spectrophotometer. It features a comprehensive selection of accessories that make it a universal system for applications such as quality control in the food industry or purity control in the pharmaceutical industry. AJ Blomesystem GmbH, in collaboration with the Hygiene and Environmental Institute in Hamburg, will introduce ENMOhydro, a new innovation in the area of information management systems. This new software system is designed for controlling automated water quality measurement networks.

The biennial "analytica" trade fair is the most important global platform for the more than 1,000 laboratory technology, analysis and biotechnology system providers in attendance. The 22nd edition of the show, which is being held at the New Munich Trade Fair Centre, is a chance for visitors from around the world to learn about innovations, the latest research findings and market opportunities in industry and science. Analytik Jena AG will be exhibiting in hall B2, booth 342 and in hall A3, booth 321. Additional information is available at
http://analytica2010.analytik-jena.com

Jena, March 11, 2010 - Analytik Jena AG, one of the leading providers of analytical and bioanalytical instruments for industrial and research applications, has won a large order from China in the field of life science. The company is supplying the Asian region with biotechnology systems manufactured by Biometra GmbH, a subsidiary based in Göttingen, Germany. Most of the revenues from the large order, valued at more than EUR 0.5 m, will be booked in the third quarter of the 2009/2010 fiscal year.

"China's rising standard of living makes it one of the strongest growing markets in the world and an attractive export target for the entire life science industry," said Klaus Berka, CEO of Analytik Jena AG. "Biometra is already generating 10 percent of its revenues through its long-standing sales partner in China. This is a remarkable achievement in light of the highly competitive Chinese market.

The large-scale order encompasses the delivery of several hundred Thermocyclers, a DNA amplification platform designed especially for biomedical and pharmaceutical research applications. Biometra GmbH, 100 percent acquired by Analytik Jena in May 2009 and integrated into the Life Science business unit, is one of the pioneers in the field of DNA polymerase chain reaction (PCR) technologies.

"In January 2010, we created and integrated our own sales structures for the life science market in China into our existing, extremely successful organization in Peking. We expect this move to expand the immense potential of our broad product portfolio in this segment. Overall, revenue growth has been excellent in the life science business thanks to our strategy and positioning as a complete provider," added Berka.

The company's Life Science business unit registered revenue growth of 488.9 percent in the first three months of the 2009/2010 fiscal year, spurred in particular by Biometra GmbH.

About Analytik Jena: Founded in 1990 as a sales and service company for analytical technology, Analytik Jena AG has established itself as one of the leading manufacturers of analytical and bioanalytical systems for industrial and scientific applications. Since the birth of the company, its success has been based on its sustainable strategy of combining the long-standing innovative strength and high-end products of Jena/Thuringia with the growth potential of international markets. In the three symbiotically related business units for specialised instruments "Analytical Instrumentation", "Life Science" and "Optics", Analytik Jena offers analytical, bioanalytical and optical products in a modern and popular segment of technology. For more information, visit www.analytik-jena.de.

Contact: Dana Schmidt, Media Relations
Phone: +49 36 41 77-92 81, Fax: +49 36 41 77-99 88
presse@analytik-jena.de, www.analytik-jena.com

Jena, December 4, 2009 — Analytik Jena AG`s molecular-genetic rapid test for direct identification of the H1N1 pathogen has been approved with immediate effect for in-vitro diagnostics. The company launched this test in October, initially for research purposes. Since then, several thousand clinical tests have been successfully performed in order to detect this influenza virus under laboratory conditions.

"This approval means that Analytik Jena can now launch two further important tests onto the market for molecular diagnostics and medical use" commented Klaus Berka, Chairman of the Executive Board of Analytik Jena AG. "Our strategy of combining hardware with molecular-diagnostic applications was first successfully implemented across the group following the integration of the new subsidiaries."

The RapidStripe H1N1 Assay KF combines isolation of viral nucleic acids on the KingFisher Flex purification machine with amplification and detection. Using the RapidStripe H1N1 Detection Assay, the user can carry out amplification and detection regardless of the nucleic acid isolation. Both test systems were developed for both Analytik Jena’s rapid cycler as well as the standard cycler produced by Göttingen-based Biometra GmbH, which was 100% acquired in May. Depending on the automated system used, the test provides a result within 2 to 4 hours.

The innovative procedure forming the basis of the two tests, that was developed within the Group and is known as the Rapid-Amplification-Hybridization (RAH) technology, combines amplification of the target nucleic acids with a specific hybridization reaction. The reactions take place in a reaction vessel, the simple visual detection or identification takes place on a test stripe.

"Analytik Jena is well and truly on the road to becoming a systems provider for molecular diagnostics", stated Berka. "We will put great effort in future into developing new products in the area of pathogenic detection — for example in the field of food safety or the investigation of ticks. In the mid-term, we will also increasingly focus on molecular tumor diagnostics in which we develop products for the detection of point mutations in ocogenes as the basis of therapeutic decision-making."

Hanover/Jena (Germany), October 7, 2009 — Analytik Jena AG is launching its newly developed rapid test for detecting the influenza virus H1N1 in time for the start of BIOTECHNICA 2009. The Thuringia-based company, an innovative supplier in the area of complete bioanalytical systems, can thus immediately commence marketing activities, initially for research purposes. The new test is a molecular-genetic rapid test for the direct identification of pathogens. The rapid test was validated both for Analytik Jena’s rapid cycler and the standard cycler of Biometra GmbH, the Goettingen-based company that was acquired in full in May, and is therefore available to a large group of users without the need for any additional investment.

"Based on our Speedcycler technology, the procedure makes it possible to detect an H1N1 infection in less than two hours," Klaus Berka, CEO of Analytik Jena, explained today at the leading biotechnology trade fair in Hanover. "The fact that no expensive equipment systems are required, as for example with real-time PCR procedures, represents a further significant competitive advantage."

The test system maps the entire process chain, from isolation of the viral RNA through to detection of an H1N1 virus infection. The underlying procedure, known as Rapid Amplification Hybridisation (RAH) technology, combines extremely rapid pathogen amplification with simple and sensitive detection on a test strip.

Analytik Jena AG is currently working at great speed in close cooperation with scientific partners to obtain approval of the test for medical applications. A particular benefit of the test is that in the future it will also be integrated into the Mobilab platform, which is also to be introduced as a world first at this year’s BIOTECHNICA. "This means it will soon be possible to use the testing system in places where large numbers of people congregate, such as airports," Berka continued.